Fábio Franke - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. KEYNOTE-048 w...

2019 The Lancet 2928 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 6,103

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-9417-2123

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.